Erratum: A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma (Cancer DOI: 10.1002/cncr.26510)

TY - JOUR

T1 - Erratum

T2 - A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma (Cancer DOI: 10.1002/cncr.26510)

AU - Cheson, B. D.

AU - Bartlett, N. L.

AU - Vose, J. M.

AU - Lopez-Hernandez, A.

AU - Seiz, A. L.

AU - Keating, A. T.

AU - Shamsili, S.

AU - Papadopoulos, K. P.

AU - Papadopoulos, Kyriakos P.

PY - 2012/9/1

Y1 - 2012/9/1

UR - https://www.scopus.com/pages/publications/84865332727

U2 - 10.1002/cncr.27384

DO - 10.1002/cncr.27384

M3 - Comment/debate

AN - SCOPUS:84865332727

SN - 0008-543X

VL - 118

SP - 4365

JO - Cancer

JF - Cancer

IS - 17

ER -